Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III open-label single-arm study of recombinant human coagulation factor VIIa in hemophilia with inhibitors
CTR20220560Phase 3Completed
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Mar 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of coagulation factor VIIa in hemophilia A and hemophilia B (HB), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Hemostatic efficacy rate within 12 hours and Activity recovery rate after first dose. Started Mar 2022; status: completed.
02
Drugs
coagulation factor VIIa
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on CTR20220560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220560.